在心脏衰竭中与炎症和冠状动脉微血管功能障碍相关的机制
概括
心脏衰竭与保存的喷射分数 (HFpEF) 与炎症和并发症有关. 本综述探讨了炎症如何驱动HFpEF,重点关注冠状动脉微血管功能障碍和潜在的治疗方法.
科学领域:
- 心脏病学
- 免疫学
- 病理生理学
背景情况:
- 超过一半的心力衰竭患者患有心力衰竭与保存的喷射分数 (HFpEF).
- HFpEF与许多并发症有关,包括高血压,肥胖,糖尿病,慢性脏病和COPD.
- 目前尚不完全了解HFpEF的致病性,因此治疗选择有限.
研究的目的:
- 审查HFpEF中炎症与冠状动脉微血管功能障碍 (CMD) 的分子机制.
- 讨论目前针对HFpEF的炎症途径的治疗策略.
主要方法:
- 对HFpEF,并发症,炎症和CMD的文献综述.
- 对因炎症引起的心肌功能障碍所涉及的分子通路的分析.
- 对HFpEF的当前治疗方法的综合.
主要成果:
- 通过冠状动脉微血管炎症越来越多地被认为是心肌功能障碍的驱动因素.
- 在HFpEF中,炎症对CMD的发展和进展起着至关重要的作用.
- 目前正在研究与炎症和CMD相关的几种治疗点.
结论:
- 冠状动脉微血管炎症是将并发症与HFpEF联系起来的关键机制.
- 针对炎症途径和CMD是新型HFpEF疗法的前景.
- 需要进一步研究以阐明复杂的病原体和优化HFpEF的治疗策略.
更多相关视频
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
2.5K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
相关概念视频
Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Myocarditis I: Introduction
28
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
28
Coronary Artery Disease II: Pathophysiology
33
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
33
Heart Failure I: Introduction
52
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
52
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
